Inventiva (NASDAQ:IVA) Sees Unusually-High Trading Volume - What's Next?

Key Points

• Inventiva S.A. experienced a trading surge with approximately 33,751 shares traded, slightly down from the previous session's volume of 35,615 shares, with the stock priced at $5.96.
• Analysts have given mixed ratings on Inventiva, with a consensus target price of $16.14, where six analysts rated it as a Buy and one as a Sell.
• Wealth Enhancement Advisory Services LLC increased its stake in Inventiva by 54.5%, reflecting growing institutional interest in the company.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) shares saw unusually-high trading volume on Friday . Approximately 33,751 shares were traded during mid-day trading, a decline of 5% from the previous session's volume of 35,615 shares.The stock last traded at $5.96 and had previously closed at $5.87.

Analysts Set New Price Targets

IVA has been the topic of a number of recent research reports. Piper Sandler began coverage on Inventiva in a report on Wednesday, August 27th. They issued an "overweight" rating and a $26.00 target price on the stock. Wall Street Zen raised Inventiva to a "hold" rating in a research note on Saturday, October 18th. Weiss Ratings reissued a "sell (d-)" rating on shares of Inventiva in a research note on Wednesday, October 8th. Canaccord Genuity Group reissued a "buy" rating and issued a $20.00 target price on shares of Inventiva in a research report on Tuesday, September 30th. Finally, HC Wainwright lifted their target price on shares of Inventiva from $20.00 to $24.00 and gave the stock a "buy" rating in a research report on Thursday, October 9th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Inventiva has an average rating of "Moderate Buy" and a consensus target price of $16.14.

Inventiva Trading Up 5.1%

The stock's 50-day moving average is $5.40 and its 200 day moving average is $4.07.

Institutional Investors Weigh In On Inventiva

A hedge fund recently raised its stake in Inventiva stock. Wealth Enhancement Advisory Services LLC increased its stake in shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) by 54.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,558 shares of the company's stock after buying an additional 5,843 shares during the quarter. Wealth Enhancement Advisory Services LLC's holdings in Inventiva were worth $50,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 19.06% of the company's stock.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.